An unusual cause of cancer mimicry following liver transplantation

Sirolimus is an approved anti-rejection agent following liver or kidney transplantation that works through inhibition of the mammalian target of rapamycin (mTOR). As sirolimus functions through a pathway independent of calcineurin inhibition, it may have less potential for nephrotoxicity and carcino...

Full description

Bibliographic Details
Main Authors: Karim Qumosani, Natasha Chandok
Format: Article
Language:English
Published: Elsevier 2012-01-01
Series:Annals of Hepatology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S166526811931498X